Table 1.
Sociodemographic and clinical characteristics of the sample (n=304)
| Mean (SD) | Range | |
|---|---|---|
| Age, years | 63.5 (12.2) | 27 – 93 |
| Child-Pugh score | 6.1 (1.3) | 5 – 12 |
|
| ||
| N | Percent | |
|
| ||
| Female | 73 | 24% |
| Baseline Treatment | ||
| TACE | 133 | 44% |
| 90Y | 82 | 27% |
| No treatment | 33 | 11% |
| Resection | 20 | 7% |
| Embolization | 17 | 6% |
| RFA laparoscopic | 12 | 4% |
| RFA open | 6 | 2% |
| Nexavar | 1 | <1% |
| Sample | ||
| QOL study | 83 | 27% |
| Intervention | 54 | 18% |
| RCT | 117 | 38% |
| Surgical | 50 | 16% |
| Stage of disease (n=4 missing) | ||
| I | 6 | 2% |
| II | 9 | 3% |
| III | 43 | 14% |
| IV | 242 | 81% |
| Disease progression from Time 1 to Time 2 (n=2 missing) | ||
| Response to treatment | 33 | 11% |
| Stable | 57 | 19% |
| Progression | 115 | 38% |
| Not Available | 62 | 21% |
| Deceased | 35 | 12% |
| Disease progression from Time 2 to Time 3 (n=2 missing) | ||
| Response to treatment | 33 | 11% |
| Stable | 55 | 18% |
| Progression | 85 | 28% |
| N/A | 67 | 22% |
| Deceased | 62 | 21% |
| Disease progression from Time 3 to Time 4 (n=2 missing) | ||
| Response to treatment | 22 | 7% |
| Stable | 59 | 20% |
| Progression | 76 | 25% |
| N/A | 55 | 18% |
| Deceased | 90 | 30% |